Cargando…
Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
BACKGROUND: The epidermal growth factor receptor (EGFR) is overexpressed in colorectal cancer (CRC), and is correlated with poor prognosis, making it an attractive target for monoclonal antibody (mAb) therapy. A component of the therapeutic efficacy of IgG1 mAbs is their stimulation of antibody-depe...
Autores principales: | Oppenheim, D E, Spreafico, R, Etuk, A, Malone, D, Amofah, E, Peña-Murillo, C, Murray, T, McLaughlin, L, Choi, B S, Allan, S, Belousov, A, Passioukov, A, Gerdes, C, Umaña, P, Farzaneh, F, Ross, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950873/ https://www.ncbi.nlm.nih.gov/pubmed/24496456 http://dx.doi.org/10.1038/bjc.2014.35 |
Ejemplares similares
-
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020) -
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers
por: Bordoloi, Devivasha, et al.
Publicado: (2023) -
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019) -
“Universal Flu Vaccine”: Can NK Cell-mediated ADCC Tip the Scales?
por: Hassane, Maya, et al.
Publicado: (2016) -
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)